提供支持According to VCBeat, JOINTECH Ltd. ("JOINTECH"), a technology company focusing on R&D and production of robot-assisted systems of orthopedic surgery, has completed the Series A funding round of tens of millions yuan from Baidu Ventures. Haoyue Capital serves as the exclusive financial adviser for this round. Proceeds of this financing will be used to promote clinical trials of "ARTHROBOT", the company's first robot assistant for joint replacement.
Founded in 2018, JOINTECH has quickly become a leading medical device company providing accurate joint replacement solutions in China by virtue of its experienced team and self-developed robotic-assisted surgical systems.
With many years of experience in surgical navigation and surgical robot R&D, the team of JOINTECH has not only developed innovative technologies, but also closely met the needs of doctors in clinical applications, effectively solving the major problems of traditional artificial joint replacement surgery. In terms of products, the surgical robot with independent intellectual property rights of JOINTECH provides an overall solution for joint surgery, covering the whole "preoperative, intraoperative and postoperative" process.
The robotic-assisted surgical systems of JOINTECH can not only improve the accuracy and stability of joint surgery, but also prevent doctors and patients from intraoperative radiation exposure, reduce the occurrence of postoperative complications for patients, and shorten the learning curve for doctors.
As a global medical device company with orthopedic implants at its core, JOINTECH is currently valued at about 380 billion yuan and its "Mako" robotic joint surgery system is widely used worldwide. "ARTHROBOT" has entered the clinical trial, and the registration progress is far ahead of other competitors. It is expected to become the first domestic robot assistant for joint replacement to obtain the NMPA.
About Baidu Ventures (BV)
BV invests in deep tech companies pushing the frontiers that enable artificial intelligence as well as companies building applications that were previously impossible without AI.
BV is a financial investor focusing on the Seed, Series A, and Series B of companies across China, North America & Europe, with teams in all three geographies.
Haoyue Capital is a boutique investment bank focused on China's medical health.
渝公网安备 50011202502165号
